Lung cancer’s patient information gap: the pharmaphorum podcastFor episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, Share XLung cancer’s patient information gap: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/lung-cancers-patient-information-gap
Adapting for the future of oncology trialsAdvanced analytical solutions provider Cytel is at the forefront of rapid changes in oncology R&D. We spoke with Share XAdapting for the future of oncology trialshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/cytel-future-adaptive-trials-cancer/
Making behaviour change stickBehaviour change is set to become a key skill for pharma companies in the very near future – Share XMaking behaviour change stickhttps://pharmaphorum.com/digital/making-behaviour-change-stick/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Medical music to calm the nervesDominic Tyer looks at the clinical studies evaluating music as an unconventional but promising treatment for some patients. Share XMedical music to calm the nerveshttps://pharmaphorum.com/r-d/views-analysis-r-d/medical-music-calm-nerves/
Digital therapies and the future of healthThe health sector is going through rapid and radical transformation and new technologies are redesigning the way healthcare Share XDigital therapies and the future of healthhttps://pharmaphorum.com/views-analysis-digital/digital-therapies-and-the-future-of-health/
AI in the Gartner Hype CycleWhen you’re surrounded by media coverage about new technology, it can be difficult to discern what really matters. Share XAI in the Gartner Hype Cyclehttps://pharmaphorum.com/views-analysis-digital/ai-in-the-gartner-hype-cycle/
Patients in the driving seatMany pharma companies talk about the importance of ‘patient centric’ clinical trials and involving patients in trial design – Share XPatients in the driving seathttps://pharmaphorum.com/r-d/patients-in-the-driving-seat/
Moving from autologous to allogeneic ACT paradigmsWe have come so far in a relatively short time with Adoptive Cellular Transfer (ACT). The two marketed Share XMoving from autologous to allogeneic ACT paradigmshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/icon-allogeneic-adoptive-cellular-transfer/
